Basit öğe kaydını göster

dc.contributor.authorSaez-Comet, Luis
dc.contributor.authorCervello, Gonzalo Salvador
dc.contributor.authorSebastiani, Gian Domenico
dc.contributor.authorSquatrito, Danilo
dc.contributor.authorSzucs, Gabriella
dc.contributor.authorCaminal-Montero, Luis
dc.contributor.authorCastro, Antoni
dc.contributor.authorColodro Ruiz, Agustin
dc.contributor.authorDoria, Andrea
dc.contributor.authorDomer, Thomas
dc.contributor.authorGonzalez-Echavarri, Cristina
dc.contributor.authorGremese, Elisa
dc.contributor.authorHoussiau, Frederic A.
dc.contributor.authorHuizinga, Tom
dc.contributor.authorIsenberg, David
dc.contributor.authorLuliano, Annamaria
dc.contributor.authorJacobsen, Soren
dc.contributor.authorJimenez-Alonso, Juan
dc.contributor.authorKovacs, Laszlo
dc.contributor.authorMariette, Xavier
dc.contributor.authorMosca, Marta
dc.contributor.authorNived, Ola
dc.contributor.authorOristrell, Joaquim
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorRascon, Javier
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.contributor.authorSaez-Comet, Luis
dc.contributor.authorSalvador Cervello, Gonzalo
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.contributor.authorVoskuyl, Alexandre
dc.contributor.authorvan Vollenhoven, Ronald
dc.contributor.authorInana, Murat
dc.contributor.authorRyden-Aulin, Monica
dc.contributor.authorBoumpas, Dimitrios
dc.contributor.authorBultink, Irene
dc.contributor.authorRubio, Jose Luis Callejas
dc.date.accessioned2021-03-03T09:03:30Z
dc.date.available2021-03-03T09:03:30Z
dc.date.issued2016
dc.identifier.citationRyden-Aulin M., Boumpas D., Bultink I., Rubio J. L. C. , Caminal-Montero L., Castro A., Colodro Ruiz A., Doria A., Domer T., Gonzalez-Echavarri C., et al., "Off-label use of rituximab for systemic lupus erythematosus in Europe", LUPUS SCIENCE & MEDICINE, cilt.3, sa.1, 2016
dc.identifier.otherav_1af7a189-0c8e-4413-a092-5dead74079ba
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/23419
dc.identifier.urihttps://doi.org/10.1136/lupus-2016-000163
dc.description.abstractObjectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy.
dc.language.isoeng
dc.subjectİmmünoloji ve Romatoloji
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.titleOff-label use of rituximab for systemic lupus erythematosus in Europe
dc.typeMakale
dc.relation.journalLUPUS SCIENCE & MEDICINE
dc.contributor.departmentKarolinska Institutet (Karolinska Institute) , ,
dc.identifier.volume3
dc.identifier.issue1
dc.contributor.firstauthorID229801


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster